Abstract One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer C1.0 cm in size to increase survival and is considered for women with tumors 0.5-0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors C1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5-0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.
Introduction
Human epidermal growth factor 2 (HER2) is involved in various cellular processes, including growth and differentiation. About 15-20 % of breast cancers overexpress HER2 [1] ; those tumors are associated with worse clinical outcomes [2] . In 1996, a recombinant monoclonal antibody that specifically targets HER2, trastuzumab, was approved for advanced cancer patients whose tumors overexpress HER2. In 2005, the combined results of two adjuvant trials showed a 50 % reduction in recurrence with a year of trastuzumab in addition to chemotherapy for those with tumors C1.0 cm in size. Trastuzumab was approved for adjuvant use in 2006 [3] [4] [5] . Despite the inclusion of tumors C1 cm in the trials, the National Comprehensive Cancer Network recommends consideration of trastuzumab therapy for patients with tumors 0.5-0.9 cm in size as well.
With regard to duration, a meta-analysis reported worse survival for subjects who received \12 months of therapy. A trial comparing 6-12 months showed superiority for 12 months of therapy [6] . It remains controversial as to whether trastuzumab in conjunction with hormonal therapy alone confers a survival benefit in women with early-stage disease. Because trastuzumab can cause cardiac dysfunction, it is contraindicated in patients with impaired left ventricular function.
While adjuvant treatment for breast cancer has improved its survival [7, 8] , not all patients receive appropriate treatment [9] ; some do not receive recommended therapy at all [10] , while others discontinue therapy early [9, 11] . These deviations can be associated with worse survival [9, 12, 13] .
The breast cancer quality of care study (BQUAL) is a multi-site prospective cohort study to identify the rates and reasons for non-initiation and early discontinuation of adjuvant therapy among women with resected breast cancer [14] . In this study, we previously reported on noninitiation of adjuvant chemotherapy [15] and hormonal therapy [16] . In the current study, we investigate the rate of non-initiation of trastuzumab among women whose tumors overexpress HER2 and, among those who initiated trastuzumab, we determined early discontinuation rates.
Patients and methods
The BQUAL study has been previously described [14] . From 2006 to 2010, we recruited women newly diagnosed with primary breast cancer, stages I-III, from New York City (Columbia University Medical Center, CUMC, and Mount Sinai School of Medicine, MSSM), Detroit (Henry Ford Health System, HFHS) and Northern California (Kaiser-Permanente of Northern California, KPNC). We excluded women with a history of cancer other than nonmelanoma skin cancer and non-English speakers. Subjects were required to have a telephone, to be able to provide informed consent and to be 20 years or older.
Trained research assistants interviewed each subject by telephone three times: within 3 months of diagnosis or prior to receipt of a third cycle of chemotherapy; 
Study variables

Demographic and tumor factors
Demographic characteristics, including age, race/ethnicity, education, annual household income, employment, marital status, and recruitment site, were collected at baseline. Tumor characteristics (AJCC stage, tumor grade and size, nodal status, ER/PR and HER2 status) and comorbidities reported from 12 months prior to 3 months after diagnosis were abstracted from the medical record or obtained from administrative databases; comorbidities were used to derive a Charlson comorbidity index score [17] .
Chemotherapy-related factors
Factors related to chemotherapy included self-reported referral to a medical oncologist, whether the participant was under oncologist care, if chemotherapy was discussed, offered or recommended, and if so, by whom.
Outcome measure
The patient's initiation of trastuzumab was determined as described above, by review of pharmacy records or chart abstraction. Early discontinuation was defined as stopping trastuzumab before 9 months of therapy was completed. For those who discontinued trastuzumab early, medical records were reviewed to determine the reason.
Data analysis
Trastuzumab initiators and non-initiators were compared using Fisher's or Chi square tests for categorical variables and Student's t tests for continuous variables. Cronbach's alpha was used to assess internal consistency and reliability of scale measures. The sample size was too small to undertake multivariate analysis. Similar analyses compared those who discontinued trastuzumab therapy early to those who did not. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Between May 2006 and June 2010, 1479 women with newly diagnosed non-metastatic breast cancer were identified and contacted. Of these, 122 (8.2 %) refused to participate and 212 (14.3 %) were ineligible, leaving 1145 women eligible for the study. Of these, 152 were HER2-positive (13.3 %). Twenty had tumors 0.5-0.9 cm in size (13 %), while 126 had a tumor C1.0 cm (79 %); we used this group as our main analytic sample because the guidelines for trastuzumab use are definitive for this population (Fig. 1) . Of this group, 110 (87.3 %) initiated trastuzumab as part of their adjuvant therapy. Of the 20 women with tumors 0.5-0.9 cm, 5 (25 %) initiated trastuzumab. Table 1 contains selected characteristics of the 126 women with HER2-positive tumors C1 cm. Patients who did not initiate trastuzumab were older, had earlier stage tumors, better grade, and were less likely to have received adjuvant chemotherapy than those who initiated trastuzumab.
We used 9 months of therapy as a cutoff for early discontinuation of trastuzumab. We found that, of the 119 initiators, 18 (15 %) discontinued early. None of the early discontinuers recurred or died prior to the 9-month cutoff. Of these 18 early discontinuers, 15 (83 %) had an indication of cardiotoxicity in their medical record, most commonly a reduced left ventricular ejection fraction from baseline. Table 2 compares characteristics of the 119 women with HER2-positive tumors who initiated adjuvant trastuzumab, separated into those who discontinued early versus those who completed therapy. None of the factors examined were statistically associated with early discontinuation.
Discussion
In this prospective cohort study evaluating trastuzumab use in women with non-metastatic HER2-positive breast cancer, we were reassured to find that 87 % of women for whom there was a definitive indication for trastuzumab received the drug. Furthermore, of those who began treatment with trastuzumab, 85 % completed the year of prescribed therapy. Of those who stopped early, the vast majority did so appropriately because of signs of cardiotoxicity.
There have been a few prior studies of compliance with adjuvant trastuzumab in the community. One study utilized data from the North Trent Cancer Network in the United Kingdom. The study looked at 1319 early-stage breast cancer patients and found that 185 (14 %) were HER2-positive. Of these, 56 (30 %) did not receive trastuzumab. The majority were not treated because of age [75 years, frailty, poor performance status, and/or comorbidities, while 10 (15 %) had a prior cardiac history and 13 (20 %) refused therapy [18] . Barron and colleagues [19] used data [20] . A recent study using the SEER-Medicare database reported that among elderly women with breast cancer who initiated adjuvant trastuzumab that 81.7 % completed 9 months of therapy, similar to our findings; of those who discontinued early, 8.1 % were hospitalized for cardiac problems [21] . In general, it appears that compliance with adjuvant chemotherapy treatment is high when there are clearcut guidelines supported by good evidence. We previously found within the BQUAL Study that for breast cancer patients whose indications for adjuvant chemotherapy were definitive by NCCN guidelines, 90 % were compliant [15] .
Older age has been a deterrent to breast cancer adjuvant therapy use. Indeed, for those [65 years, adjuvant chemotherapy use has been significantly lower in colon, rectal, and ovarian cancer as well. We found, for example, that only 22 % of patients over age 70 initiated adjuvant chemotherapy for breast cancer [15] , consistent with prior studies [22] [23] [24] [25] . Clinical trials have shown that the elderly benefit from chemotherapy, and age is not the best criterion for these decisions [26] . For adjuvant trastuzumab, in this study we found that 4/13 (31 %) women [70 did not initiate its use.
This study has several strengths and limitations. Our patient population includes women from community practices, academic medical centers, and health maintenance organizations, increasing generalizability. We also had excellent recruitment and retention. The patient population was mostly insured, so it was probably of higher socioeconomic status than the general population. We excluded subjects without a telephone and non-English speakers, decreasing generalizability.
In conclusion, we found that the majority of women with HER2-positive breast cancer initiated trastuzumab adjuvant therapy. Once initiated, the majority completed the recommended one year of treatment. Most who discontinued early did so because of the drug's known cardiotoxic effects. As in other settings, adjuvant chemotherapy utilization is high among those for whom it is most likely to be beneficial, and oncologists appear to adhere to the guidelines best under those circumstances.
